AhmadTarhiniMDPhD

Hematologic Oncology, Melanoma

Director, Cutaneous Clinical and Translational Research

Overview of Dr. Tarhini

Dr. Ahmad Tarhini is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Kaunas Medical Institute and has been in practice 23 years. Dr. Tarhini accepts several types of health insurance, listed below. He is one of 171 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
Moffitt Cancer Center
12902 USF Magnolia Dr
Tampa, FL 33612
Book by Phone+1(813) 519-4790

Fax+1 404-778-2177
Is this information wrong?

Education & Training

UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2003 - 2006
UPMC Medical EducationResidency, Internal Medicine, 2000 - 2003
Kaunas Medical InstituteClass of 1999

Certifications & Licensure

FL State Medical License 2019 - 2025
GA State Medical License 2018 - 2020
OH State Medical License 2017 - 2019
PA State Medical License 2001 - 2018

Clinical Trials

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 2006 Oct 01
Completed
Phase 1
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2007 Jun 01
Completed
Phase 2
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2008 Oct 01
Completed
Phase 1
Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma Start of enrollment: 2006 Nov 01
Completed
Phase 2
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia Start of enrollment: 2008 Sep 01
Terminated
Phase 1
Pilot Study of IFN α2b for Melanoma Patients Start of enrollment: 2009 Sep 01
Terminated
Early Phase 1
Melanoma Molecular Profiling Analysis Start of enrollment: 2008 May 01
Completed
Computed Tomography (CT) Perfusion Imaging of Lung Cancer Start of enrollment: 2009 Jun 01
Terminated
Not Applicable
Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2009 Jul 01
Terminated
Phase 1
Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer Start of enrollment: 2010 Sep 01
Terminated
Phase 2
Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer Start of enrollment: 2009 Sep 01
Terminated
Phase 1
Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma Start of enrollment: 2009 Dec 01
Completed
Early Phase 1
AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer Start of enrollment: 2011 Aug 01
Completed
Phase 1, Phase 2
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2011 Jan 18
Completed
Phase 2
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
Active, not recruiting
Phase 3
A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma Start of enrollment: 2012 Jun 03
Completed
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors Start of enrollment: 2012 Jul 24
Completed
Phase 1
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2013 Jan 18
Active, not recruiting
Phase 2
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Completed
Phase 3
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Start of enrollment: 2013 Jul 01
Terminated
Phase 1, Phase 2
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Dec 13
Active, not recruiting
Phase 3
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
Active, not recruiting
Phase 2
High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Start of enrollment: 2015 Nov 10
Active, not recruiting
Phase 3
Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone Start of enrollment: 2016 Oct 01
Withdrawn
Phase 1, Phase 2
A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study Start of enrollment: 2016 Sep 01
Terminated
Phase 2
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors Start of enrollment: 2018 May 30
Active, not recruiting
Phase 1
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma Start of enrollment: 2021 May 24
Recruiting
Early Phase 1
Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma Start of enrollment: 2021 Oct 22
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Treatment of Stage III Resectable Melanoma-Adjuvant and Neoadjuvant Approaches.
Ella Castellano, Islam Eljilany, Ahmad A Tarhini> ;Cancer Journal. 2024 Mar 25
A Bioinformatics Tool for Identifying Intratumoral Microbes from the ORIEN Dataset.
Tinoco Suarez, G. R., Tinoco Suarez, G. R., Tinoco Suarez, G. R., Tinoco Suarez, G. R., Wang, C., Ma, A., Li, Y., McNutt, M., Zhang, S., Zhu, J., Hoyd, R., Wheeler, C....> ;Cancer Research Communications. 2024 Feb 5
Comparing the rate of immunotherapy treatment change due to toxicity by sex.
Chua, K., Liu, H., Schneider, B., Sterling, J., Singer, E., Kronstedt, S., Kaldany, A., Srivastava, A., Tarhini, A., Gatti-Mays, M., Gaughan, E., Hu-Lieskovan, S., Alj...> ;Cancer Reports. 2024 Feb 1
The T Cell Immunoscore as a Reference for Biomarker Development Utilizing Real-World Data from Patients with Advanced Malignancies Treated with Immune Checkpoint Inhib...
Islam Eljilany, Payman Ghasemi Saghand, James Chen, Aakrosh Ratan, Martin McCarter, John Carpten, Howard Colman, Alexandra P Ikeguchi, Igor Puzanov, Susanne Arnold, Mi...> ;Cancers. 2023 Oct 10
2 citations
Translation of AI into oncology clinical practice.
Issam El Naqa, Aleksandra Karolak, Yi Luo, Les Folio, Ahmad A Tarhini, Dana Rollison, Katia Parodi> ;Oncogene. 2023 Oct 1
1 citations
Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field.
Islam Eljilany, Ella Castellano, Ahmad A Tarhini> ;Cancers. 2023 Aug 16
1 citations
Clinical updates in neoadjuvant immunotherapy for melanoma before surgery.
Mariam Saad, Ella Castellano, Ahmad A Tarhini> ;Expert Review of Clinical Immunology. 2023 Aug 28
PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing.
Alyssa N Obermayer, Darwin Chang, Gabrielle Nobles, Mingxiang Teng, Aik-Choon Tan, Xuefeng Wang, Y Ann Chen, Steven Eschrich, Paulo C Rodriguez, G Daniel Grass, Soheil...> ;BMC Bioinformatics. 2023 Jun 28
Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma.
Julian A Marin-Acevedo, Bethany M Withycombe, Youngchul Kim, Andrew S Brohl, Zeynep Eroglu, Joseph Markowitz, Ahmad A Tarhini, Kenneth Y Tsai, Nikhil I Khushalani> ;Cancers. 2023 Jun 14
2 citations
The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors.
Caroline E Wheeler, Samuel S Coleman 4th, Rebecca Hoyd, Louis Denko, Carlos H F Chan, Michelle L Churchman, Nicholas Denko, Rebecca D Dodd, Islam Eljilany, Sheetal Har...> ;Biorxiv. 2023 May 25
2 citations
A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab.
Iyad Kobeissi, Islam Eljilany, Tala Achkar, William A LaFramboise, Lucas Santana-Santos, Ahmad A Tarhini> ;International Journal of Molecular Sciences. 2023 May 3
1 citations
Granulomatous and Sarcoid-like Immune-Related Adverse Events following CTLA4 and PD1 Blockade Adjuvant Therapy of Melanoma: A Combined Analysis of ECOG-ACRIN E1609 and...
Islam Eljilany, Arish Noor, Mahati Paravathaneni, Ibrahim Yassine, Sandra J Lee, Megan Othus, James Moon, John M Kirkwood, Vernon K Sondak, Antoni Ribas, Kenneth F Gro...> ;Cancers. 2023 Apr 29
3 citations
Leptomeningeal Disease (LMD) in Patients with Melanoma Metastases.
Mariam Lotfy Khaled, Ahmad A Tarhini, Peter A Forsyth, Inna Smalley, Yolanda Piña> ;Cancers. 2023 Mar 21
DRPPM-PATH-SURVEIOR: Plug-and-Play Survival Analysis of Pathway-level Signatures and Immune Components.
Alyssa Obermayer, Darwin Chang, Gabrielle Nobles, Mingxiang Teng, Aik-Choon Tan, Xuefeng Wang, Steven Eschrich, Paulo Rodriguez, G Daniel Grass, Soheil Meshinchi, Ahma...> ;Research Square. 2023 Mar 14
12 citations
Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.
Zeynep Eroglu, Shifra Krinshpun, Ekaterina Kalashnikova, Sumedha Sudhaman, Turkan Ozturk Topcu, Matt Nichols, Justin Martin, Katherine M Bui, Charuta C Palsuledesai, M...> ;Cancer. 2023 Jun 1
Neoadjuvant Therapy in Melanoma: Where Are We Now?
Mariam Saad, Ahmad A Tarhini> ;Current Oncology Reports. 2023 Apr 1
1 citations
Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients.
Allison Betof Warner, Ahmad Tarhini, Barinder Kang, Antonio Nakasato, You-Li Ling, Rohan Shah, Jackson Tang, Jeetvan Patel> ;Melanoma Research. 2023 Feb 1
102 citations
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Atkins, M., Lee, S., Chmielowski, B., Tarhini, A., Cohen, G., Truong, T., Moon, H., Davar, D., O'Rourke, M., Stephenson, J., Curti, B., Urba, W., Brell, J., Funchain, ...> ;Journal of Clinical Oncology. 2023 Jan 10
1 citations
Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of ...
Joseph M Unger, Amy Darke, Megan Othus, Thach-Giao Truong, Nikhil Khushalani, Kari Kendra, Karl D Lewis, Bryan Faller, Pauline Funchain, Elizabeth I Buchbinder, Ahmad ...> ;JAMA Oncology. 2023 Feb 1
Sentinel Lymph Node Gene Expression Signature Predicts Recurrence-Free Survival in Cutaneous Melanoma.
Lilit Karapetyan, William Gooding, Aofei Li, Xi Yang, Andrew Knight, Hassan M Abushukair, Danielle Vargas De Stefano, Cindy Sander, Arivarasan Karunamurthy, Monica Pan...> ;Cancers. 2022 Oct 11
32 citations
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
Sungjune Kim, Evan Wuthrick, Dukagjin Blakaj, Zeynep Eroglu, Claire Verschraegen, Ram Thapa, Matthew Mills, Khaled Dibs, Casey Liveringhouse, Jeffery Russell, Jimmy J ...> ;Lancet. 2022 Sep 24
Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III tria...
Laurie E McLouth, Yue Zheng, Stephanie Smith, F Stephen Hodi, Uma N Rao, Gary I Cohen, Thomas T Amatruda, Shaker R Dakhil, Brendan D Curti, Ibrahim Nakhoul, Sreenivasa...> ;Quality of Life Research. 2023 Jan 1
10 citations
Neoadjuvant immunotherapy of locoregionally advanced solid tumors.
Ahmad A Tarhini, Jennifer R Eads, Kathleen N Moore, Valerie Tatard-Leitman, John Wright, Patrick M Forde, Robert L Ferris> ;Journal for Immunotherapy of Cancer. 2022 Aug 1
7 citations
Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma.
Samuel Coleman, Mengyu Xie, Ahmad A Tarhini, Aik Choon Tan> ;Molecular Carcinogenesis. 2023 Jan 1
5 citations
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade c...
Mariam Saad, Sandra J Lee, Aik Choon Tan, Issam M El Naqa, F Stephen Hodi, Lisa H Butterfield, William A LaFramboise, Walter Storkus, Arivarasan D Karunamurthy, Jose C...> ;Journal of Translational Medicine. 2022 Jun 3
Join now to see all

Journal Articles

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced Melanoma
Igor Puzanov, Kim A Margolin, Jose Lutzky, Ahmad Tarhini, Nageatte Ibrahim, JAMA Oncology
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Kim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine

Lectures

United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-Î±2b for resected high-risk melanoma.
2019 ASCO Annual Meeting - 6/1/2019
Clinical and economic outcomes associated with sequential treatment in BRAF mutant advanced melanoma patients.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Association of Community Cancer Centers(ACCC) 30th National Conference
Association of Community Cancer Centers (ACCC), Boston, Massachusetts - 10/2/2013
Association of Community Cancer Centers(ACCC) 30th National Conference
Association of Community Cancer Centers (ACCC), Boston, Massachusetts - 10/2/2013
Join now to see all

Authored Content

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020
Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced MelanomaJuly 2020

Press Mentions

Covid-19 Two Years on: Persistent Symptoms of Clinical Trial Disruption Trouble Certain Therapy AreasMarch 31st, 2022
The Opdualag Effect: Designing First-Line Melanoma Clinical Trials After Anti-LAG-3 Antibody ApprovalMarch 23rd, 2022
Advanced Melanoma Survival and Costs Differ in Treatment Combo and Sequence ComparisonJune 4th, 2018
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Hospital Affiliations

H. Lee Moffitt Cancer Center and Research InstituteTampa, Florida

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Texas BlueChoice
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Oklahoma
First Choice
First Health PPO
Great West PPO
Health Net Oregon PPO
HealthAmerica HealthAssurance PPO
Highmark BCBS ClassicBlue
Highmark BCBS PPOBlue
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
ODS Network
Providence Health System Personal Option
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment